Interferons in Relapsing-Remitting Multiple Sclerosis: Are There Benefits from Long-Term Use?

ISSN： 1172-7047

Source： CNS Drugs, Vol.18, Iss.15, 2004-01, pp. : 1057-1070

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Cost Effectiveness of Interferon- -1a in the Treatment of Relapsing-Remitting Multiple Sclerosis: An Econometric Model

By Lepen C.

Clinical Drug Investigation, Vol. 23, Iss. 9, 2003-01 ,pp. : 571-581

Adis International

Access to resources Recommend Favorite

Fingolimod: A Review of its Use in the Management of Relapsing-Remitting Multiple Sclerosis

By Scott Lesley J.

CNS Drugs, Vol. 25, Iss. 8, 2011-08 ,pp. : 673-698

Adis International

Access to resources Recommend Favorite

Glatiramer Acetate: A Review of its Use in Relapsing-Remitting Multiple Sclerosis

By Simpson D. Noble S. Perry C.

CNS Drugs, Vol. 16, Iss. 12, 2002-01 ,pp. : 825-850

Adis International

Access to resources Recommend Favorite

Laquinimod beneficial in relapsing-remitting MS?

Inpharma, Vol. 1, Iss. 1645, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Cladribine tablets for the treatment of relapsing–remitting multiple sclerosis

By Comi Giancarlo Hartung Hans-Peter Kurukulasuriya Nuwan C Greenberg Steven J Scaramozza Matthew

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 1, 2013-01 ,pp. : 123-136

Informa Healthcare

Access to resources Recommend Favorite